BACKGROUND: Although many patients with Kaposi sarcoma (KS) in sub-Saharan Africa are diagnosed with AIDS Clinical Trials Group (ACTG) T1 disease, T1 staging insufficiently captures clinical heterogeneity of advanced KS. Using a representative community-based sample, we detailed disease severity at diagnosis to inform KS staging and treatment in sub-Saharan Africa. METHODS: We performed rapid case ascertainment on people living with HIV, aged 18 years or older, newly diagnosed with KS from 2016 to 2019 at 3 clinic sites in Kenya and Uganda to ascertain disease stage as close as possible to diagnosis. We reported KS severity using ACTG and WHO staging criteria and detailed measurements that are not captured in the current staging systems. RESULTS: We performed rapid case ascertainment within 1 month for 241 adults newly diagnosed with KS out of 389 adult patients with suspected KS. The study was 68% men with median age 35 years and median CD4 count 239. Most of the patients had advanced disease, with 82% qualifying as ACTG T1 and 64% as WHO severe/symptomatic KS. The most common ACTG T1 qualifiers were edema (79%), tumor-associated ulceration (24%), extensive oral KS (9%), pulmonary KS (7%), and gastrointestinal KS (4%). There was marked heterogeneity within T1 KS, with 25% of patients having 2 T1 qualifying symptoms and 3% having 3 or more. CONCLUSION: Most of the patients newly diagnosed with KS had advanced stage disease, even in the current antiretroviral therapy "treat-all" era. We observed great clinical heterogeneity among advanced stage patients, leading to questions about whether all patients with advanced KS require the same treatment strategy.
BACKGROUND: Although many patients with Kaposi sarcoma (KS) in sub-Saharan Africa are diagnosed with AIDS Clinical Trials Group (ACTG) T1 disease, T1 staging insufficiently captures clinical heterogeneity of advanced KS. Using a representative community-based sample, we detailed disease severity at diagnosis to inform KS staging and treatment in sub-Saharan Africa. METHODS: We performed rapid case ascertainment on people living with HIV, aged 18 years or older, newly diagnosed with KS from 2016 to 2019 at 3 clinic sites in Kenya and Uganda to ascertain disease stage as close as possible to diagnosis. We reported KS severity using ACTG and WHO staging criteria and detailed measurements that are not captured in the current staging systems. RESULTS: We performed rapid case ascertainment within 1 month for 241 adults newly diagnosed with KS out of 389 adult patients with suspected KS. The study was 68% men with median age 35 years and median CD4 count 239. Most of the patients had advanced disease, with 82% qualifying as ACTG T1 and 64% as WHO severe/symptomatic KS. The most common ACTG T1 qualifiers were edema (79%), tumor-associated ulceration (24%), extensive oral KS (9%), pulmonary KS (7%), and gastrointestinal KS (4%). There was marked heterogeneity within T1 KS, with 25% of patients having 2 T1 qualifying symptoms and 3% having 3 or more. CONCLUSION: Most of the patients newly diagnosed with KS had advanced stage disease, even in the current antiretroviral therapy "treat-all" era. We observed great clinical heterogeneity among advanced stage patients, leading to questions about whether all patients with advanced KS require the same treatment strategy.
Authors: Fred Okuku; Elizabeth M Krantz; James Kafeero; Moses R Kamya; Jackson Orem; Corey Casper; Warren Phipps Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: Mikiko Senga; Alpha Koi; Lina Moses; Nadia Wauquier; Philippe Barboza; Maria Dolores Fernandez-Garcia; Etsub Engedashet; Fredson Kuti-George; Aychiluhim Damtew Mitiku; Mohamed Vandi; David Kargbo; Pierre Formenty; Stephane Hugonnet; Eric Bertherat; Christopher Lane Journal: Philos Trans R Soc Lond B Biol Sci Date: 2017-05-26 Impact factor: 6.237
Authors: Christopher De Boer; Nixon Niyonzima; Jackson Orem; John Bartlett; S Yousuf Zafar Journal: Infect Agent Cancer Date: 2014-05-20 Impact factor: 2.965
Authors: Nader Kim El-Mallawany; William Kamiyango; Jimmy Villiera; Jeremy S Slone; Carrie L Kovarik; Liane R Campbell; Anurag K Agrawal; Dirk P Dittmer; Anthony B Eason; Saeed Ahmed; Gordon E Schutze; Michael E Scheurer; Peter N Kazembe; Parth S Mehta Journal: J Glob Oncol Date: 2017-12-22
Authors: Vini Fardhdiani; Lucas Molfino; Ana Gabriela Zamudio; Rolanda Manuel; Gilda Luciano; Iza Ciglenecki; Barbara Rusch; Laurence Toutous Trellu; Matthew E Coldiron Journal: Infect Agent Cancer Date: 2018-01-19 Impact factor: 2.965
Authors: Cavin E Bekolo; Mohamed M Soumah; Ousseni W Tiemtore; Abdourahimi Diallo; Joseph-Desire Yuma; Letizia Di Stefano; Carol Metcalf; Mohamed Cisse Journal: BMC Cancer Date: 2017-12-02 Impact factor: 4.430
Authors: Esther E Freeman; Nicole C McCann; Aggrey Semeere; Krishna P Reddy; Miriam Laker-Oketta; Helen Byakwaga; Pamela P Pei; Maya E Hajny Fernandez; Samson Kiprono; Naftali Busakhala; Jeffery N Martin; Toby Maurer; Ingrid V Bassett; Kenneth A Freedberg; Emily P Hyle Journal: Lancet Glob Health Date: 2022-08 Impact factor: 38.927
Authors: Sigrid Collier; Aggrey Semeere; Helen Byakwaga; Miriam Laker-Oketta; Linda Chemtai; Anjuli D Wagner; Ingrid V Bassett; Kara Wools-Kaloustian; Toby Maurer; Jeffrey Martin; Samson Kiprono; Esther E Freeman Journal: Implement Sci Commun Date: 2022-05-13